Tecogen Inc. approved equity grants and salary increases for its top executives, including CEO Abinand Rangesh, on June 26, 2026. The board granted restricted stock and incentive stock options to five named executive officers, with the CEO receiving 174,081 restricted shares and 26,041 options; other executives received smaller awards. The equity vests equally over four years, and the options have an exercise price of $5.17 per share. Base salaries were raised 5% for the CEO to $220,500 and 3% for the other officers.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding TECOGEN INC/WALTHAM MA (TGEN)?

Major stakeholders currently include Vanguard Capital Management LLC ($2.0M), Bard Associates INC ($1.8M), Clear Harbor Asset Management, LLC ($1.7M). Based on the latest 13F filings, there are a total of 61 tracked investment funds and institutions maintaining positions in TGEN.

What is the overall institutional sentiment toward TGEN recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $18.9M, driven by 27 managers accumulating shares while 39 reduced their exposure.

Which institutions have been selling or reducing their TGEN positions?

In the latest period, 19 funds trimmed their holdings, and 20 managers completely exited their positions. The aggregate reported sell value was $22.9M.

Are there any notable investors adding TGEN to their portfolios?

Yes, buying activity remains notable. 12 institutions opened new positions in {ticker}, and 15 existing holders added to their shares. The total reported buy value for the quarter amounted to $7.9M.